secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001140361-23-024002
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO Q1 net loss $25.0M, cash $72.3M; appoints interim CEO; GD3 trial on track
--------------------------------------------------------------------------------

- Net loss of $25.0M for Q1 2023 vs $29.8M in Q1 2022; R&D expenses $17.3M, G&A $7.9M.
- Cash and equivalents $72.3M as of March 31, 2023; expected runway into Q1 2024.
- Plan to initiate registrational Phase 2/3 trial for Gaucher disease type 3 in H2 2023, subject to regulatory alignment.
- Appointed CFO Erik Ostrowski as interim CEO, succeeding Geoff MacKay; board searching for permanent CEO.
- Collaborator-sponsored Phase 1/2 trial for Hunter syndrome (MPS-II) initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000114036123024002/0001140361-23-024002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000114036123024002/brhc20052752_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-024002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer